351 related articles for article (PubMed ID: 18031594)
41. Effects of bisphosphonates on fracture incidence and bone metabolism in rheumatoid arthritis patients in general practice taking long-term corticosteroid therapy: a retrospective study.
Katayama K; Matsuno T
Clin Drug Investig; 2008; 28(3):149-58. PubMed ID: 18266400
[TBL] [Abstract][Full Text] [Related]
42. Risk of fracture and treatment to prevent osteoporosis-related fracture in postmenopausal women. A review.
Martens MG
J Reprod Med; 2003 Jun; 48(6):425-34. PubMed ID: 12856513
[TBL] [Abstract][Full Text] [Related]
43. Prevention of vertebral fractures in osteoporosis: mixed treatment comparison of bisphosphonate therapies.
Jansen JP; Bergman GJ; Huels J; Olson M
Curr Med Res Opin; 2009 Aug; 25(8):1861-8. PubMed ID: 19530978
[TBL] [Abstract][Full Text] [Related]
44. Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis.
Nakamura T; Nakano T; Ito M; Hagino H; Hashimoto J; Tobinai M; Mizunuma H;
Calcif Tissue Int; 2013 Aug; 93(2):137-46. PubMed ID: 23644930
[TBL] [Abstract][Full Text] [Related]
45. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies.
Boonen S; Laan RF; Barton IP; Watts NB
Osteoporos Int; 2005 Oct; 16(10):1291-8. PubMed ID: 15986101
[TBL] [Abstract][Full Text] [Related]
46. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
47. Assessment of the relationship between age and the effect of risedronate treatment in women with postmenopausal osteoporosis: a pooled analysis of four studies.
Boonen S; Klemes AB; Zhou X; Lindsay R
J Am Geriatr Soc; 2010 Apr; 58(4):658-63. PubMed ID: 20345865
[TBL] [Abstract][Full Text] [Related]
48. Bisphosphonates for post-menopausal osteoporosis: are they all the same?
Rizzoli R
QJM; 2011 Apr; 104(4):281-300. PubMed ID: 21258058
[TBL] [Abstract][Full Text] [Related]
49. Treatment of primary osteoporosis in men.
Giusti A; Bianchi G
Clin Interv Aging; 2015; 10():105-15. PubMed ID: 25565793
[TBL] [Abstract][Full Text] [Related]
50. Bisphosphonates for osteoporosis in primary biliary cirrhosis.
Rudic JS; Giljaca V; Krstic MN; Bjelakovic G; Gluud C
Cochrane Database Syst Rev; 2011 Dec; (12):CD009144. PubMed ID: 22161446
[TBL] [Abstract][Full Text] [Related]
51. Preventing nonvertebral osteoporotic fractures with extended-interval bisphosphonates: regimen selection and clinical application.
Cole RE; Harris ST
Medscape J Med; 2009; 11(1):12. PubMed ID: 19295933
[TBL] [Abstract][Full Text] [Related]
52. Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis.
Reginster JY
Expert Opin Pharmacother; 2005 Oct; 6(13):2301-13. PubMed ID: 16218890
[TBL] [Abstract][Full Text] [Related]
53. Osteodensitometry in healthy postmenopausal women.
Prescrire Int; 2008 Apr; 17(94):68-72. PubMed ID: 18536138
[TBL] [Abstract][Full Text] [Related]
54. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.
Kanis JA; Johansson H; Oden A; McCloskey EV
Bone; 2009 Jun; 44(6):1049-54. PubMed ID: 19254788
[TBL] [Abstract][Full Text] [Related]
55. Osteoporosis: trials and tribulations.
Seeman E
Am J Med; 1997 Aug; 103(2A):74S-87S; discussion 87S-89S. PubMed ID: 9302899
[TBL] [Abstract][Full Text] [Related]
56. Effectiveness of Oral Bisphosphonates in Reducing Fracture Risk Among Oral Glucocorticoid Users: Three Matched Cohort Analyses.
Amiche MA; Lévesque LE; Gomes T; Adachi JD; Cadarette SM
J Bone Miner Res; 2018 Mar; 33(3):419-429. PubMed ID: 29068496
[TBL] [Abstract][Full Text] [Related]
57. Bisphosphonates for Paget's disease of bone in adults.
Corral-Gudino L; Tan AJ; Del Pino-Montes J; Ralston SH
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD004956. PubMed ID: 29192423
[TBL] [Abstract][Full Text] [Related]
58. Management of postmenopausal osteoporosis and the prevention of fractures.
Gambacciani M; Levancini M
Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
[TBL] [Abstract][Full Text] [Related]
59. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
Pyon EY
Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
[TBL] [Abstract][Full Text] [Related]
60. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.
Recker RR; Kendler D; Recknor CP; Rooney TW; Lewiecki EM; Utian WH; Cauley JA; Lorraine J; Qu Y; Kulkarni PM; Gaich CL; Wong M; Plouffe L; Stock JL
Bone; 2007 Apr; 40(4):843-51. PubMed ID: 17182297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
